Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aronex Pharma (ARNX) -- Ignore unavailable to you. Want to Upgrade?

To: Robert Floyd who wrote (196)	12/8/1998 2:09:00 PM
From: Vendit™	Read Replies (1) \| Respond to of 320

Sorry sir but I'm not familiar with the term EU submission. Is EU short for a compound? fda.gov

To: Robert Floyd who wrote (196)	12/10/1998 12:58:00 PM
From: Dexter Enders	Read Replies (1) \| Respond to of 320

MAA status: I sent two e-mails to get this response.... ---------------------------------------------------------------- From: Connie Stout <cstout@aronex-pharm.com>Add to Address Book To:'Dexter Enders' <enders@yahoo.com> Subject: RE: Status of Nyotran Date: Thu, 10 Dec 1998 10:16:09 -0600 We have amended our agreement with Ferrer to enable Abbott to pursue an optimal registration and commercialization strategy in all international markets. The discussion regarding the MAA is part of this strategy. I hope the above answers your question. Thank you. Connie Stout ------------------------------------------------------------------- It still doesn't really answer the question. I don't think she can give any real information on the status....